Research Interest：
Professor Luyuan Li obtained his BS degree in Biochemistry from Sichuan University, Chengdu, China, in 1982, and his PhD degree from Cornell University Medical School, New York, the United States in 1988, also in Biochemistry. Having completed his postdoctoral training in the Department of Chemistry at Pennsylvania State University, he joined the Lederle Laboratory in New York in 1991 as a Senior Scientist. He joined the faculty of Georgetown University Medical Center, Washington, DC, in 1995, as an Assistant Professor of Biochemistry and Molecular Biology, and a Member of the Lombardi Cancer Center. He moved to University of Pittsburgh School of Medicine in 2002 as an Associate Professor of Pathology and Member of the UPMC Hillman Cancer Center, and Member of McGowan Institute for Regenerative Medicine. He moved to China in 2008 to join the faculty of Nankai University, Tianjin, and has been a Professor of Pharmacology in Nankai University College of Pharmacy. Research in Li laboratory has focused on vascular and lymphatic endothelial cell biology and the molecular mechanisms of modulation of tumor hypoxic microenvironment. His work has contributed to the discovery of human tumor necrosis factor superfamily-15 (TNFSF15) and human rhomboid family-1 (RHBDF1) genes and their functions. His study on human angiopoietin-1 gene leads to the proposal of the hypothesis that stabilization of tumor neovasculature with vascular smooth muscle cells may inhibit tumor growth. Professor Li has published over 120 papers, with a H-index of 35, in Angiogenesis, Blood, Cancer Research, Cell Research, Circulation Research, Journal of Biological Chemistry, Journal of Immunology, Journal of Pathology, the FASEB Journal, Proceedings of the National Academy of Sciences USA, Protein and Cell, and Signal Transduction and Targeted Therapy, among others.
Education History：
1978-1982，College of Biology, Sichuan University，Bachelor of Biochemistry
1982-1988, Medical College, Cornell University, Doctor of Philosophy in Biochemistry
Selected Publications:
1. Alternative splicing of the human rhomboid family-1 gene RHBDF1 inhibits epidermal growth factor receptor activation.Renpeng Ji, Qianqian Shi, Yixin Cao, Jingyue Zhang, Cancan Zhao, Huanyu Zhao, Yasra Sayyed, Li F, and Lu-Yuan Li*.2022, J. Biol. Chem. 298(6)102033
2. TNFSF15 facilitates differentiation and polarization of macrophages toward M1 phenotype to inhibit tumor growth. Can-Can Zhao, Qiu-Ju Han, Hao-Yan Ying, Xiang-Xiang Gu, Na Yang, Lu-Yuan Li*, Qiang-Zhe Zhang*. 2022, OncoImmunology, 11:1, 2032918
3. RHBDF1 promotes AP-1-activated endothelial–mesenchymal transition in tumor fibrotic stroma formation. Shan Gao, Li-Song Zhang, Lei Wang, Nan-Nan Xiao, Hui Long, Yi-Lun Yin, Yu-Meng Yang, Zhen Xi, Lu-Yuan Li*，Zhi-Song Zhang*. 2021. Signal Transduction and Targeted Therapy. doi.org/10.1038/s41392-021-00597-1
4. Real-time monitoring of caspase-3/8 activity by self-assembling nanofiber probes in living cells. Li-Song Zhang, Hong-Lei Xu, Ying Xia, Jian-Peng Bi, Chuan-Zeng Zhang, Zhen Xi, Lu-Yuan Li *and Zhi-Song Zhan*. 2021. Chem. Commun., 57:797
5. Counterbalance: modulation of VEGF/VEGFR activities by TNFSF15. Gui-Li Yang and Lu-Yuan Li*. 2018, Signal Transduction and Targeted Therapy, doi.org/10.1038/s41392-018-0023-8
